Pamela Kunz, MD, director, Center for Gastrointestinal (GI) Cancers, Smilow Cancer Hospital and Yale Cancer Center, associate professor of internal medicine (medical oncology), chief, GI Medical Oncology, vice chief, Diversity, Equity, and Inclusion, Medical Oncology, Yale School of Medicine, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors (NETs).

Tailoring treatments to patients with NETs and continuing to develop more effective therapies are important elements of care for this patient population, says Kunz. However, the caveat is that many patients with well-differentiated NETs can live for many years with metastatic disease, so it is important that the risks associated with the therapeutic intervention don't outweigh the risks of the disease, Kunz explains. Moreover, it is important that therapies elicit disease control and tumor shrinkage while still allowing patients to maintain a good quality of life, Kunz adds. 

For patients with slower growing cancers, it's even more important to consider the safety profile of a particular therapy, Kunz continues. This makes tailoring therapies to be patient-specific in order to minimize toxicities crucial, Kunz concludes. 

Videos

Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors. 


Dr. Kunz on the Importance of Tailoring Treatments to Patients With NETs 

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide on the overall treatment paradigm for patients with neuroendocrine tumors.

The approval gave creditability to the use of somatostatin analogs as antiproliferative agents, Kunz says. Many oncologists have long been using the somatostatin analog octreotide as an antiproliferative agent for the treatment of small bowel neuroendocrine tumors, despite it not having FDA label for that use, Kunz suggests.

As a result of lanreotide (Somatuline Depot) being applied to a larger patient population in the CLARINET study, Kunz says many oncologists are expanding the patient population for which they consider somatostatin analogs as antiproliferative agents.

View more from the 2015 GI Cancer Symposium

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide. 

Pamela L. Kunz

Articles

Dr. Kunz on the Importance of Tailoring Treatments to Patients With NETs

Dr. Kunz on the Impact of Lanreotide's Approval for Neuroendocrine Tumors